

Kenneth Cusi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6525105/publications.pdf>

Version: 2024-02-01

154
papers

27,662
citations

13865
67
h-index

9103
144
g-index

157
all docs

157
docs citations

157
times ranked

22706
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	7.3	4,738
2	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023.	7.3	2,935
3	A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2006, 355, 2297-2307.	27.0	1,584
4	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.	1.3	1,486
5	Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. <i>Journal of Clinical Investigation</i> , 2000, 105, 311-320.	8.2	953
6	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	27.0	833
7	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2016, 165, 305.	3.9	732
8	Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. <i>Gastroenterology</i> , 2012, 142, 711-725.e6.	1.3	711
9	Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2784-2791.	3.6	629
10	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 313-324.	11.4	566
11	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. <i>Gastroenterology</i> , 2007, 133, 496-506.	1.3	500
12	A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 2461-2474.	0.6	447
13	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2231-2238.	3.6	404
14	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4059-4067.	3.6	349
15	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1389-1397.	7.3	348
16	Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling. <i>Diabetes</i> , 2005, 54, 1640-1648.	0.6	333
17	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
18	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	2.1	323

#	ARTICLE	IF	CITATIONS
19	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 70, 711-724.	7.3	305
20	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4059-4067.	3.6	285
21	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017, 40, 419-430.	8.6	256
22	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. <i>JHEP Reports</i> , 2019, 1, 312-328.	4.9	251
23	The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2010, 10, 306-315.	4.2	239
24	A global view of the interplay between non-alcoholic fatty liver disease and diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 284-296.	11.4	232
25	Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009, 50, 1087-1093.	7.3	231
26	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	1.3	229
27	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 250-260.	7.1	228
28	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 60, 167-174.	3.7	223
29	Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes Care</i> , 2012, 35, 873-878.	8.6	214
30	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019, 42, 1481-1488.	8.6	202
31	Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2009, 13, 545-563.	2.1	192
32	Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 65, 1132-1144.	7.3	191
33	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	17.8	174
34	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021, 44, 399-406.	8.6	173
35	Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. <i>Liver International</i> , 2015, 35, 2139-2146.	3.9	169
36	Saroglitazar, a PPAR α/β Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	7.3	163

#	ARTICLE	IF	CITATIONS
37	The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 61, 153-160.	7.3	156
38	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 393-406.	11.4	155
39	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 558-566.e2.	4.4	154
40	Nonalcoholic fatty liver disease in type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 141-149.	2.3	150
41	Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 829-836.	3.6	143
42	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. <i>Journal of Hepatology</i> , 2020, 72, 613-626.	3.7	143
43	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. <i>Drugs</i> , 2013, 73, 1-14.	10.9	139
44	Nonalcoholic fatty liver disease (<sc>NAFLD</sc>) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1630-1634.	4.4	137
45	Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014, 59, 2178-2187.	7.3	129
46	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 644-652.	3.6	127
47	Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E484-E494.	3.5	126
48	Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. <i>Cardiovascular Diabetology</i> , 2010, 9, 9.	6.8	120
49	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 812-821.	4.4	117
50	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 290-297.	8.6	113
51	Normalization of Plasma Glucose Concentration by Insulin Therapy Improves Insulin-Stimulated Glycogen Synthesis in Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 462-468.	0.6	109
52	New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). <i>Annals of Medicine</i> , 2009, 41, 265-278.	3.8	108
53	Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 632-638.	8.6	108
54	Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 765-781.	3.2	107

#	ARTICLE	IF	CITATIONS
55	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. <i>Diabetologia</i> , 2016, 59, 1112-1120.	6.3	102
56	The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2013, 13, 329-341.	4.2	101
57	Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015, 62, 405-411.	3.7	98
58	Pioglitazone in the treatment of NASH: the role of adiponectin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 769-775.	3.7	97
59	Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1775-E1781.	3.5	89
60	Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E311-E319.	3.5	88
61	Pharmacological management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1183-1195.	3.4	86
62	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 29-38.	3.6	82
63	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 54, 837-845.	7.3	74
64	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2007, 47, 565-570.	3.7	73
65	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020, 19, 674-690.	1.5	72
66	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	17.8	72
67	Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. <i>Obesity</i> , 2021, 29, 1950-1960.	3.0	70
68	Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM. <i>Diabetes Care</i> , 1995, 18, 843-851.	8.6	68
69	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3327-3336.	3.6	68
70	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2950-2961.	3.6	66
71	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a <i>post hoc</i> analysis of the AWARD programme. <i>Diabetic Medicine</i> , 2018, 35, 1434-1439.	2.3	59
72	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019, 67, 303-311.	1.6	59

#	ARTICLE	IF	CITATIONS
73	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	1.3	58
74	Prediabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 751-764.	3.2	55
75	PPAR α -induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. <i>Liver International</i> , 2021, 41, 2659-2670.	3.9	51
76	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E163-E173.	3.5	50
77	Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1090-1099.	3.4	49
78	Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option. <i>Journal of Investigative Medicine</i> , 2018, 66, 7-10.	1.6	49
79	Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 275-279.	8.6	49
80	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. <i>Clinical Diabetes and Endocrinology</i> , 2016, 2, 9.	2.7	45
81	Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?. <i>American Journal of Medicine</i> , 2020, 133, 536-543.	1.5	43
82	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 401-410.	3.7	40
83	Use of a metabolomic approach to noninvasively diagnose nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1702-1709.	4.4	39
84	Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Diabetes Reports</i> , 2020, 20, 59.	4.2	39
85	Improved experimental data processing for UHPLC- ² H/MS lipidomics applied to nonalcoholic fatty liver disease. <i>Metabolomics</i> , 2017, 13, 1.	3.0	38
86	Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. <i>Contemporary Clinical Trials</i> , 2017, 61, 33-38.	1.8	38
87	Unmet Needs in Hispanic/Latino Patients with Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 2011, 124, S2-S9.	1.5	37
88	Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> , 2018, 41, 187-192.	8.6	37
89	Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1348-1351.	8.6	37
90	Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. <i>Hepatology</i> , 2019, 69, 2318-2322.	7.3	37

#	ARTICLE	IF	CITATIONS
91	A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. <i>Liver International</i> , 2020, 40, 82-88.	3.9	36
92	Effect of all-extremity high-intensity interval training vs. moderate-intensity continuous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trial. <i>Experimental Gerontology</i> , 2019, 116, 46-53.	2.8	31
93	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	7.3	31
94	An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 211-225.	3.2	30
95	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	8.6	30
96	Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 50-58.	4.4	29
97	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 56-61.	3.7	28
98	Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 105-114.	4.7	26
99	Plasma Thyroid Hormone Concentration is Associated with Hepatic Triglyceride Content in Patients with Type 2 Diabetes. <i>Journal of Investigative Medicine</i> , 2016, 64, 63-68.	1.6	26
100	Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. <i>Journal of Diabetes</i> , 2019, 11, 223-231.	1.8	26
101	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	8.1	26
102	Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. <i>Hepatology</i> , 2017, 65, 4-7.	7.3	25
103	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	1.8	25
104	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	3.4	25
105	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. <i>Journal of Endocrinology</i> , 2019, 241, 293-305.	2.6	25
106	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Clinical Lipidology</i> , 2012, 7, 471-481.	0.4	23
107	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018, 9, 752.	3.5	23
108	Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2009, 9, 200-207.	4.2	22

#	ARTICLE	IF	CITATIONS
109	Chronic Low-Dose Lipid Infusion in Healthy Patients Induces Markers of Endothelial Activation Independent of Its Metabolic Effects. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 141-146.	1.7	21
110	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. <i>Hepatology Communications</i> , 2021, 5, 938-946.	4.3	21
111	Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1344-1352.	8.6	21
112	Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2014, 13, 159-170.	0.9	20
113	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. <i>Journal of Investigative Medicine</i> , 2020, 68, 743-747.	1.6	13
114	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 969, 219-223.	2.3	12
115	Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. <i>European Journal of Endocrinology</i> , 2021, 184, 587-596.	3.7	12
116	Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. <i>Cell Reports Medicine</i> , 2021, 2, 100474.	6.5	12
117	The relationship between hepatitis C virus infection and diabetes: Time for a divorce?. <i>Hepatology</i> , 2014, 60, 1121-1123.	7.3	11
118	Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. <i>PLoS ONE</i> , 2021, 16, e0251449.	2.5	11
119	Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. <i>Obesity</i> , 2022, 30, 1231-1238.	3.0	11
120	Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. <i>Gut</i> , 2018, 67, 1371-1371.	12.1	10
121	Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. <i>Current Opinion in Lipidology</i> , 2020, 31, 364-366.	2.7	10
122	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1472-1480.	3.7	10
123	Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities. <i>Obesity</i> , 2019, 27, 1099-1106.	3.0	8
124	Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. <i>PLoS ONE</i> , 2019, 14, e0219855.	2.5	7
125	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	3.0	7
126	Editorial: diabetes, obesity and clinical inertia—the recipe for advanced <sc>NASH</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1220-1221.	3.7	6

#	ARTICLE	IF	CITATIONS
127	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4360-e4371.	3.6	6
128	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. Annals of Internal Medicine, 2017, 166, 230.	3.9	5
129	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. Hepatology, 2017, 66, 296-297.	7.3	5
130	Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. Nutrition Research, 2021, 88, 34-43.	2.9	5
131	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	4.4	5
132	Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores. JMIR Medical Informatics, 2022, 10, e36997.	2.6	5
133	Insulin sensitizers in nonalcoholic steatohepatitis. Hepatology, 2011, 53, 1404-1405.	7.3	4
134	Healthcare Transition from Pediatric to Adult Medical Homes. Endocrine Practice, 2014, 20, 714-720.	2.1	4
135	Reply to "œstatins and non-alcoholic steatohepatitis". Metabolism: Clinical and Experimental, 2017, 66, e3-e5.	3.4	4
136	Re: "œAssociation Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. (Thyroid 2018;28:1270-1284). Thyroid, 2019, 29, 452-452.	4.5	4
137	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	8.6	4
138	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
139	Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. Journal of Investigative Medicine, 2018, 66, 661-668.	1.6	3
140	Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187-192. Diabetes Care, 2018, 41, e137-e138.	8.6	2
141	Letter to the Editor: "œHepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content". Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5249-5250.	3.6	2
142	Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. Liver International, 2015, 35, 2341-2342.	3.9	1
143	1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes, 2020, 69, 1461-P.	0.6	1
144	A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3076-e3077.	3.6	1

#	ARTICLE	IF	CITATIONS
145	Diabetes medications improve cardiovascular outcomes. Current Opinion in Lipidology, 2016, 27, 633-635.	2.7	0
146	Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. Clinical Pharmacology and Therapeutics, 2017, 101, 444-446.	4.7	0
147	Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352. Diabetes Care, 2021, 44, e167-e167.	8.6	0
148	Plasma Branch Chain and Aromatic Amino Acid Levels are Associated with Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD). FASEB Journal, 2013, 27, .	0.5	0
149	Induction of Mitochondrial Tricarboxylic Acid Cycle is Sustained in Mice with Nonalcoholic Steatohepatitis (NASH). FASEB Journal, 2015, 29, 258.4.	0.5	0
150	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. Contemporary Diabetes, 2018, , 47-69.	0.0	0
151	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. Journal of the Endocrine Society, 2020, 4, .	0.2	0
152	Reply. Gastroenterology, 2022, , .	1.3	0
153	Response to: "Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?" Obesity, 2022, , .	3.0	0
154	JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. Journal of Clinical Lipidology, 2022, 16, 115-127.	1.5	0